Establishment of Kirin Brewery Co., Ltd.
History of Kyowa KirinLearn more about our heritage and
contributions to healthcare
Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.
龙8体育Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).
Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C.
龙8体育Invention of the process of L-glutamic acid production by fermentation (a world first).
Initiation of full-scale involvement in the pharmaceutical business.
Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.
Release of 5-FU, an anticancer drug.
Release of Leunase, an anticancer drug.
龙8体育The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.
龙8体育Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).
龙8体育elease of ESPO?, an erythropoietin (EPO) drug.
龙8体育Release of GRAN?, G-CSF drug.
Release of Coniel, a remedy for hypertension and agina pectoris.
龙8体育Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.
龙8体育The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP?, a long-acting erythropoietic stimulating drug.
Established COMPLEGENT?, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary.
龙8体育Capital alliance between Kyowa Hakko Group and Kirin Group.
Release of REGPARA?, a drug for secondary hyperparathyroidism.
龙8体育Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd.
龙8体育Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma.
龙8体育Introduced "Commitment to Life".
Acquired ProStrakan Group plc.
龙8体育Launch of Poteligeo? in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)
龙8体育Launch of NOURIAST? tablets 20 mg in Japan, a novel antiparkinsonian agent.
龙8体育ProStrakan Completes Acquisition of Archimedes.
Launch of Sustained-Duration G-CSF Product G-LASTA? in Japan.
Rebranding Western Pharmaceutical Subsidiaries to "Kyowa Kirin".
Launch of LUMICEF? for Psoriasis Treatment in Japan.
龙8体育Crysvita? approved in the US and Europe, sales to start as a treatment for patients with X-linked hypophosphatemia.
Poteligeo? approved in the US and Europe as a treatment for mycosis fungoides (MF) and Sézary syndrome (SS).
龙8体育Trade name changed to current "Kyowa Kirin Co., Ltd." from Kyowa Hakko Kirin Co., Ltd.
龙8体育Crysvita? launched in Japan for the treatment of FGF23-related Hypophosphatemic Rickets and Osteomalacia.
龙8体育Nourianz? launched in the US for use in Parkinson's disease.